Pharmacological Treatment of a Patient with Life-long Obesity and Heterozygous Complete loss-of-function Melanocortin 4 Receptor Mutation

Emily Cooper
Additional contact information
Emily Cooper: Diabesity Research Foundation, USA

Current Research in Diabetes & Obesity Journal, 2016, vol. 1, issue 3, 57-60 2Volume: 1

Abstract: The heterozygous melanocortin 4 receptor (MC4R) mutation is considered a primary factor in 2% to 4% of patients with obesity. Pharmacological treatment, including long-term, is emerging as a new standard for obese patients; however, there are no published reports on treatment outcomes in obese patients with documented MC4R mutations. Weight loss occurs with diet restriction or bariatric surgery and is often followed by a weight regain phase in patients with or without the MC4R mutation, indicating the need for an alternative approach to weight loss such as pharmacological treatment.

Keywords: juniper publishers; diabetes journals; diabetes impact factor; endocrinology journal; endocrinology impact factor; endocrinology research journal; endocrinology research articles; diabetes open access journals; Obesity Journal; Diabetes & Obesity Journal (search for similar items in EconPapers)
Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555562.pdf (application/pdf)
https://juniperpublishers.com/crdoj/CRDOJ.MS.ID.555562.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jcrdoj:v:1:y:2016:i:3:p:57-60

DOI: 10.19080/CRDOJ.2016.01.555562

Access Statistics for this article

Current Research in Diabetes & Obesity Journal is currently edited by Sophia Mathis

More articles in Current Research in Diabetes & Obesity Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().